Abstract

IntroductionProstate cancer (PCa) is a public health problem worldwide, which has been related to sexually transmitted infections (STIs). The risk allele (T) of rs10993994 (C>T) polymorphism in the MSMB gene encodes for a prostate secretory protein of 94 amino acids (PSP94), conferring susceptibility to STIs development. This allele has also been associated with an increment (~35%) of PCa risk. Nonetheless, the genetic contribution of this polymorphism has not been evaluated in the Mexican men yet as well as neither whether the STIs history modifies this association.Material and methodsSocio-demographic characteristics, sexual, and reproductive history of incident PCa cases (n=322) and 628 healthy population controls matched by age (±5 years) were analysed as well as the genotyping of rs10993994 polymorphism in Mexico City males. Unconditional logistic regression models were used to estimate the odds ratios for PCa, PCa aggressiveness and age of onset. The interaction between STI history and MSMB polymorphism were evaluated including an interaction term between both variables.Results and discussionsNo frequency differences were found between cases and controls. Nevertheless, when adjusting by age, PCa family history in first-degree relatives, residence place and the STIs history were done, TT genotype carriers had almost three-fold higher odds (OR 2.61; IC 95% 1.06, 6.44; p=0.04) of early-onset PCa (age at diagnosis <60 years). No interaction between STIs history and rs10993994 with early-onset PCa (OR 1.78; IC 95% 0.27, 11.92; p=0.55) was observed.ConclusionTo our knowledge, this is the first study that explores the role of rs10993994 as a risk factor for PCa in Mexican men. Our findings are partially consistent with a previous study that reported association between T allele in MSMB gene and early-onset PCa. Because all STIs were considered together, we do not reject a possible interaction between a specific STI (mainly fungal aetiology) and rs10993994 polymorphism.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.